Table 2 Clinicopathological features for intrinsic subtypes
| Â | All cases | ER/PR+, HER2- | ER/PR+, HER2+ | HER2 type | Basal-like | Unclassified | P |
|---|---|---|---|---|---|---|---|
Cases (%) | 471 (100) | 306 (65.0) | 41 (8.7) | 59 (12.5) | 37 (7.9) | 28 (5.9) | Â |
Mean age at diagnosis (years) | 57.3 ±12.6 | 57.1 ±12.9 | 55.2 ±8.7 | 58.5 ±12.0 | 57.6 ±13.7 | 59.9 ±13.8 | 0.57 (Analysis of variance) |
Menopausal status at diagnosis | 0.8 (Fisher) | ||||||
Premenopausal | 169 (35.9) | 115 (37.6) | 15 (36.6) | 18 (30.5) | 11 (29.7) | 10 (35.7) | |
Postmenopausal | 302 (64.1) | 191 (62.4) | 26 (63.4) | 41 (69.5) | 26 (70.3) | 18 (64.3) | |
Stage | 0.1 (Cochran-Mantel-Haenszel) | ||||||
0 | 57 (12.1) | 41 (13.4) | 2 (4.9) | 8 (13.6) | 1 (2.7) | 5 (17.9) | |
I | 138 (29.3) | 97 (31.7) | 16 (39.0) | 9 (15.2) | 9 (24.3) | 7 (25.0) | |
IIA, IIB | 232 (49.3) | 139 (45.4) | 19 (46.3) | 34 (57.6) | 24 (64.9) | 16 (57.1) | |
IIIA, IIIB, IIIC | 40 (8.5) | 27 (8.8) | 4 (9.8) | 7 (11.9) | 2 (5.4) | 0 (0) | |
IV | 4 (0.8) | 2 (0.7) | 0 (0) | 1 (1.7) | 1 (2.7) | 0 (0) | |
Histological type | <0.01 (Fisher) | ||||||
Papillotubular carcinoma | 94 (20.0) | 49 (16.0) | 13 (31.7) | 18 (30.5) | 7 (18.9) | 7 (28.0) | |
Solid-tubular carcinoma | 83 (17.6) | 36 (11.8) | 6 (14.6) | 14 (23.7) | 23 (62.2) | 4 (14.3) | |
Scirrhous carcinoma | 194 (41.2) | 145 (47.4) | 19 (46.4) | 18 (30.5) | 3 (8.1) | 9 (32.1) | |
Noninvasive carcinoma, Paget’s disease | 65 (13.8) | 49 (16.0) | 2 (4.9) | 8 (13.6) | 1 (2.7) | 5 (17.9) | |
Others | 35 (7.4) | 27 (8.8) | 1 (2.4) | 1 (1.7) | 3 (8.1) | 3 (10.7) | |
Histological type (invasive ductal carcinoma only) | <0.01 (Fisher) | ||||||
Papillotubular carcinoma | 94 (25.3) | 49 (21.3) | 13 (34.2) | 18 (36.0) | 7 (21.2) | 7 (35.0) | |
Solid-tubular carcinoma | 83 (22.4) | 36 (15.7) | 6 (15.8) | 14 (28.0) | 23 (69.7) | 4 (20.0) | |
Scirrhous carcinoma | 194 (52.3) | 145 (63.0) | 19 (50.0) | 18 (36.0) | 3 (9.1) | 9 (45.0) | |
Lymphatic invasion | 0.31 (Fisher) | ||||||
Positive | 269 (57.1) | 169 (55.2) | 27 (65.9) | 31 (52.5) | 26 (70.3) | 16 (57.1) | |
Negative | 202 (42.9) | 137 (44.8) | 14 (34.1) | 28 (47.5) | 11 (29.7) | 12 (42.9) | |
Blood vessel invasion | 0.19 (Fisher) | ||||||
Positive | 33 (7.0) | 18 (5.9) | 4 (9.8) | 8 (13.6) | 1 (2.7) | 2 (7.1) | |
Negative | 438 (93.0) | 288 (94.1) | 37 (90.2) | 51 (86.4) | 36 (97.3) | 26 (92.9) | |
Lymph node metastases (Level I) | 0.62 (Fisher) | ||||||
Positive | 88 (18.7) | 59 (19.3) | 7 (17.1) | 14 (23.7) | 5 (13.5) | 3 (10.7) | |
Negative | 383 (81.3) | 247 (80.7) | 34 (82.9) | 45 (76.3) | 32 (86.5) | 25 (89.3) | |
Lymph node metastases (Level II) | 0.97 (Fisher) | ||||||
Positive | 30 (6.4) | 19 (6.2) | 3 (7.3) | 4 (6.8) | 2 (5.4) | 2 (7.1) | |
Negative | 441 (93.6) | 287 (93.8) | 38 (92.7) | 55 (93.2) | 35 (94.6) | 26 (92.9) | |
Lymph node metastases (Level III) | 0.56 (Fisher) | ||||||
Positive | 16 (3.4) | 11 (3.6) | 3 (7.3) | 1 (1.7) | 1 (2.7) | 0 (0) | |
Negative | 455 (96.6) | 295 (96.4) | 38 (92.7) | 58 (98.3) | 36 (97.3) | 28 (100) | |
| Â | Invasive carcinoma cases | ER /PR +, HER2- | ER/PR +, HER2+ | HER2 type | Basal- like | Unclassified | P |
Cases (%) | 406 (100%) | 257 (63.3%) | 39 (9.6%) | 51 (12.6%) | 36 (8.9%) | 23 (5.7%) | Â |
Tumor size | 0.54 (Fisher) | ||||||
≤ 2.0 cm | 272 (67.0) | 179 (69.6) | 24 (61.5) | 32 (62.7) | 24 (66.7) | 13 (56.5) | |
>2.0Â cm | 134 (33.0) | 78 (30.4) | 15 (38.5) | 19 (37.3) | 12 (33.3) | 10 (43.5) | |
Histological grade (total score) | <0.01 (Fisher) | ||||||
Grade I | 200 (49.3) | 148 (57.6) | 21 (53.8) | 14 (27.4) | 5 (13.9) | 12 (52.2) | |
Grade II or III | 201 (49.5) | 106 (41.2) | 18 (46.2) | 36 (70.6) | 31 (86.1) | 10 (43.5) | |
Unknown | 5 (1.2) | 3 (1.2) | 0 (0) | 1 (2.0) | 0 (0) | 1 (4.3) | |